VVUS

Vivus Inc
VVUS

Delisted

VVUS was delisted on the 16th of July, 2020.

Back to rankings

Healthcare Drug Manufacturers - General

Financial journalist opinion

VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma

— Innovative ethanol-free formulation intended to provide improved safety and advance care for patients undergoing high-dose conditioning therapy prior to autologous hematopoietic cell transplantation (AHCT)

VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma

VIVUS' QSYMIA® to be Featured on Health Uncensored with Dr. Drew

— Segment to air on Lifetime on Wednesday, March 19, at 7:30 AM ET/PT CAMPBELL, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced an exclusive episode on Health Uncensored with Dr. Drew.

VIVUS' QSYMIA® to be Featured on Health Uncensored with Dr. Drew

VIVUS Launches QSYMIA® in the United Arab Emirates

- A new path in weight management is now available - UAE is the first country in the Middle East to have QSYMIA® available - Rising obesity rates cost UAE nearly $12 billion annually CAMPBELL, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, announced the market approval of QSYMIA® (phentermine and topiramate extended-release capsules) CIV in the United Arab Emirates (UAE) for treatment of overweight and obesity in adults and pediatric patients, age 12 and older.

VIVUS Launches QSYMIA® in the United Arab Emirates

VIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight Management

VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For Life CAMPBELL, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- VIVUS, LLC.

VIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight Management

VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025

CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced it will provide updates to its pipeline and key program milestones during the 43rd Annual J.P. Morgan Healthcare Conference 2025.

VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025

VIVUS Shares Significant Regulatory Update on QSYMIA®

- Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure - CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its weight-management medication QSYMIA (phentermine and topiramate extended release capsules) CIV.

VIVUS Shares Significant Regulatory Update on QSYMIA®

See News Rankings

Charts implemented using Lightweight Charts™